NCT06525571 - Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

January 4, 2027

Study Completion Date

January 4, 2028

Conditions

Bladder Cancer

Interventions

DRUG

Cysview

Blue light cystoscopy uses hexyl aminolevulinate (HAL, branded in the United States as Cysview), a prodrug which accumulates in the bladder tumors and improves the tumor's visualization.

DEVICE

Karl Storz D-Light C Photodynamic Diagnostic (PDD) system

Cystoscopy procedure

Trial Locations (2)

20016

RECRUITING

Sibley Memorial Hospital, Washington D.C.

21287

RECRUITING

Johns Hopkins University School of Medicine, Baltimore